Novo Nordisk’s Etavopivat delivers major Phase 3 win in sickle cell disease
By cutting pain crises & boosting haemoglobin
By cutting pain crises & boosting haemoglobin
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
Medical experts point to a growing body of research linking energy drinks to liver injury
Advisory from Apollo Spectra Hospitals highlights hydration, nutrition, and screening as key preventive measures
American College of Cardiology and Korean Society of Cardiology convene global experts to address rising cardiometabolic burden
The CE Mark builds on the company’s ISO 13485 certification, further strengthening confidence in the platform's safety, quality and performance
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
The launch saw the presence of senior clinicians and leadership from the Manipal Hospitals network
Subscribe To Our Newsletter & Stay Updated